Key result
Peripheral vascular disease linked to ~2-fold higher urinary 11-dehydro-TXB2 excretion versus healthy controls.
Why the study?
No data are available comparing different platelet function tests in patients with peripheral vascular disease to assess in vivo platelet activation.
Is urinary 11-dehydro-TXB2 a more sensitive marker of in vivo platelet activation than other platelet specific proteins in patients with peripheral vascular disease?
Observational (n=81)
Is urinary 11-dehydro-TXB2 a more sensitive marker of in vivo platelet activation than other platelet specific proteins in patients with peripheral vascular disease?
Absolute Event Rate: 55.4% vs 26.7%
p-value: p=<0.001
Urinary 11-dehydro-TXB2 is a sensitive biomarker for detecting in vivo platelet activation in patients with peripheral vascular disease.
No takes yet. Share an insight, caveat, or question.
Platelet-monocyte aggregates may reliably gauge activation in PVD; leaves open which marker best predicts thrombotic events.
Gresele et al. (1997) conducted an observational in Peripheral arterial disease (n=81). Peripheral vascular disease vs. Healthy volunteers was evaluated on Urinary 11-dehydro-TXB2 excretion (ng/h) (p=<0.001). Peripheral vascular disease was associated with significantly higher urinary 11-dehydro-TXB2 excretion compared to healthy volunteers (55.4 vs. 26.7 ng/h, p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: